NSC16168 is a specific inhibitor of ERCC1-XPF (IC50 = 0.42 μM), which suppresses DNA repair and enhances the efficacy of cisplatin (CDDP) in cancer treatment; it potentiates cisplatin-induced cytotoxicity in cancer cells (e.g., H460 lung cancer cells) in vitro and exhibits significant anti-tumor activity in combination with cisplatin in H460 lung cancer xenograft models in vivo.